Last update 21 Nov 2024
Bumetanide analog(NeuroPro Therapeutics, Inc.)
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms bumetanide analog(NeuroPro Therapeutics, Inc.) + [1] |
Target |
Mechanism NKCC2 inhibitors(Sodium-(potassium)-chloride cotransporter 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization  NeuroPro Therapeutics, Inc.Startup |
Active Organization NeuroPro Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with Bumetanide analog(NeuroPro Therapeutics, Inc.)A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042
A Single-center, Randomized, Placebo Controlled, Double-blind, Ascending Single-dose and Repeated-dose Trial to Determine the Safety and Pharmacokinetic Profile of NPT 2042 Soft-Gelatin Capsules Administered Orally to Healthy Adult Subjects
100 Clinical Results associated with Bumetanide analog(NeuroPro Therapeutics, Inc.)
Login to view more data
100 Translational Medicine associated with Bumetanide analog(NeuroPro Therapeutics, Inc.)
Login to view more data
100 Patents (Medical) associated with Bumetanide analog(NeuroPro Therapeutics, Inc.)
Login to view more data
1
Literatures (Medical) associated with Bumetanide analog(NeuroPro Therapeutics, Inc.)01 Mar 2024Acta Crystallographica Section C Structural Chemistry
Crystal structure and Hirshfeld surface analysis of a salt of antineoplastic kinase inhibitor vandetanib
Article
Author: Liang, Minyi ; Yang, Haiwu ; Tian, Fang
100 Deals associated with Bumetanide analog(NeuroPro Therapeutics, Inc.)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Epilepsy, Reflex | Phase 1 | US | NeuroPro Therapeutics, Inc.Startup | 21 Aug 2024 |
| Alzheimer Disease | Phase 1 | US | NeuroPro Therapeutics, Inc.Startup | 20 Oct 2022 |
| Drug Resistant Epilepsy | Phase 1 | US | NeuroPro Therapeutics, Inc.Startup | 20 Oct 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free